Clinical Trials
3 trialsNCT07007559 2026-06-05
ASPEN-09-03
ALX Oncology Inc.
Phase 2 Recruiting
NCT04675333 2025-08-03
Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)
ALX Oncology Inc.
Phase 2 Active not recruiting
NCT04675294 2025-08-01
Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)
ALX Oncology Inc.
Phase 2 Active not recruiting